



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Department of Medical Studies for Children

EVALUATION OF URINARY NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN AS AN EARLY MARKER OF NEPHROPATHY IN TYPE 1 DIABETIC ADOLESCENTS

THESIS

**SUBMITTED FOR PARTIAL FULFILLMENT OF PHD DEGREE
IN CHILDHOOD STUDIES (CHILD HEALTH AND NUTRITION)
MEDICAL STUDIES DEPARTMENT**

PRESENTED BY

AHMED ISMAIL SALEM ABD-ALLAH
M.Sc. of Pediatrics, Ain Shams University

SUPERVISED BY

DR. HAYAM KAMAL NAZIF
Professor of Pediatrics, Faculty of Postgraduate Childhood studies.

DR. MOHAMED HESHAM EL HEFNAWY
Professor of Pediatrics, National Institute of Diabetes and Endocrinology.

DR. IBRAHIM ALI EMARA
Prof. of Biochemistry, National Institute of Diabetes and Endocrinology.

Faculty of Postgraduate Childhood studies
Ain Shams University

2021



وَقُلْ اَعْمَلُوا فَسَيَرَى اللّٰهُ
عَمَلَكُمْ وَرَسُولُهُ وَالْمُؤْمِنُونَ



سورة التوبة الآية (١٠٥)

اللّٰهُ
الصّٰدِقُ
العَظِيْمُ





ACKNOWLEDGEMENT

I would like to thank **ALLAH** who made all thing is possible. Words will never be able to express my deepest gratitude to all those who helped me during preparation of this study.

I am greatly honored to express my deep gratitude and faithfulness to **Prof. Dr. Hayam Kamal Nazif** Professor of Pediatrics, Faculty of Postgraduate Childhood studies for her strict supervision and revision of this work. She gave me much of her precious time, experience and support. Her valuable comments, efforts and collaboration were the causes to complete this work properly. In short no words can express my gratitude to her.

My deep thanks and appreciation to **Prof. Dr. Mohamed Hesham El Hefnawy** Professor of Pediatric Department, National Institute of Diabetes and Endocrinology for his kindness, sympathy, generous help, goodness, sincere encouragements and patience with me. His fatherly attitude and encouragement were so supportive for the completion of this work.

My deep thanks to **Prof. Ibrahim Ali Emara** Prof. of Biochemistry, National Institute of Diabetes and Endocrinology for his e for his sincere guidance, valuable directions, extraordinary effort with me and kind supervision hroughout the work.

For sure, I will never forget to thank my **Patients** to whom this study was carried out and without their cooperation, this study was never going to appear.

And finally, I would like to thank my dear **Wife** for her support, guidance and never ending care and patience for encouraging.

Ahmed

Abstract

Background and aim: Diabetic nephropathy (DN) is a major cause of morbidity and mortality among young adults with type 1 diabetes. Clinical management and therapeutic intervention from early stage of DN is of major importance to prevent progression to end-stage renal disease. Renal tubulointerstitial injury plays an important role in the development and progression of diabetic nephropathy. The aim of this case control study was to assess urinary Neutrophil Gelatinase-Associated lipocalin (uNGAL) and to evaluate as an early marker for diabetic nephropathy in type 1 diabetic adolescents.

Material and methods:

This is a case control study which involved 90 adolescents (44 males and 46 females) divided into three groups according to albumin/creatinine ratio (ACR) in urine: group I included 30 of type 1 diabetic adolescents without microalbuminuria (<30 mcg/mg) with mean age 13 ± 2.7 years, group II included 30 of type 1 diabetic adolescents with microalbuminuria (30–300 mcg/mg) with mean age 13.5 ± 2.7 years and group III included 30 of healthy controls with mean age 12.9 ± 2.0 years. In addition to uNGAL, urine albumin/creatinine ratio, serum creatinine, eGFR, FBG, HbA1C and other Common biochemical parameters were measured according to standard methods in a standard clinical laboratory and were assessed to determine their correlation with uNGAL. Data analysis was done by using (SPSS) version 20.0. P value was set significant if < 0.05 . All graphs were analyzed with graph pad version 17.0.

Results:

Patients with type 1 diabetes showed increased mean uNGAL values with respect to controls; interestingly, increased NGAL levels were already found in diabetic patients with microalbuminuria and also found in early signs of glomerular damage (normoalbuminuric)

($p=0.000$). It was increased parallel to the severity of kidney function, poor glycemic control. Patients with type 1 diabetes showed increased mean ACR values with respect to controls ($p=0.000$). Analysis of correlation revealed that uNGAL was correlated with fasting blood glucose and SBP, DBP.

CONCLUSION:

Urinary NGAL is rapidly emerging as a very promising predictive tool in a variety of renal and non-renal conditions. The horizons for its applications are rapidly expanding. It can be used early to predict many disorders, especially diabetic nephropathy in future. The present study supports these findings by showing an association between higher uNGAL levels and greater progress in diabetic nephropathy.

LAST OF CONTENTS

Contents	Page
List of Tables	I I
List of Figures	V
List of Abbreviations	VIII
Introduction	1
Aim of the work	4
Review of literature	6
CHAPTER I: Diabetes mellitus	7
CHAPTER II: Diabetic nephropathy	58
CHAPTER III: Neutrophil gelatinase-associated lipocalin (NGAL)	92
Subjects and methods	106
Results	114
Discussion	142
Summary & Conclusion	160
Recommendations	167
References	169
Arabic summary	---

LIST OF TABLES

Number	Title	Page
1	Staging of type 1 diabetes	12
2	Criteria for the diagnosis of diabetes mellitus	17
3	Current insulin inhalation systems	29
4	Criteria and classification of (DKA)	41
5	Diagnostic criteria for diabetic ketoacidosis and hyperglycemic hyperosmolar state	44
6	Pathologic classification of diabetic nephropathy	64
7	Classification of the novel biomarkers	69
8	Tubular biomarkers	71
9	Summary of some of the novel biomarkers for diabetic nephropathy	75
10	pharmacological treatment of diabetic nephropathy	84
11	Diet and alternative medicine	86
12	Summary of novel agents	88
13	Stem cell therapy in experimental diabetic nephropathy	89
14	Descriptive data of the study subjects	115
15	Comparison of anthropometric data (BMI and height) between all groups	117
16	Comparison of clinical data (SBP and DBP) between all groups	118

 List of Tables

Number	Title	Page
17	Frequency distribution of all diabetic patients (n=60) included in the study regarding Family History (FH), complications of diabetes and additional diseases with treatment.	119
18	Comparison of Diabetes Markers laboratory investigations in patients with type 1 diabetes mellitus Group I, Group II and control Group III	120
19	Comparison of liver function test investigations between patients type 1 diabetes mellitus Group I, Group II and control Group III	122
20	Comparison of Lipid profile laboratory investigations in patients with type 1 diabetes mellitus Group I, Group II and control Group III	123
21	Comparison of Kidney Function Test laboratory investigations in patients with type 1 diabetes mellitus Group I, Group II and control Group III	125
22	Comparison of laboratory markers of nephropathy in patients with type 1 diabetes mellitus Group I, Group II and control Group III	127
23	Comparison of uNGAL and ACR in relation to family history of diabetes mellitus in patients with type 1 diabetes mellitus Group I and Group II	129
24	Comparison of uNGAL and ACR in relation to family history of cardiovascular disease in patients with type 1 diabetes mellitus Group I and Group II	131
25	Comparison of uNGAL and ACR in relation to family history of renal disease in patients with type 1 diabetes mellitus Group I and Group II	133

 List of Tables

Number	Title	Page
26	Illustrates the correlation between level of uNGAL and laboratory parameter of Diabetic Group I	135
27	illustrates the correlation between level of NGAL and laboratory parameter of Diabetic Group II	138

LIST OF FIGURES

Number	Title	Page
1	The estimated number of new cases of type 1 diabetes mellitus (T1DM) in children (<15 years of age) per 100,000 individuals in 2015.	11
2	Insulin-Pump Therapy for Type 1 Diabetes Mellitus	23
3	Future strategies for successful outcome of human islet transplantation	34
4	Pathogenesis of DKA and HHS: stress, infection, or insufficient insulin. FFA, free fatty acid.	43
5	Protocol for management of adult patients with diabetic ketoacidosis and hyperglycaemic hyperosmolar state recommended by the ADA	50
6	A schematic representation of the pathogenesis of diabetic nephropathy	60
7	Characteristic histological features of diabetic nephropathy	67
8	Recommendations for the treatment of confirmed hypertension in people with diabetes.	79
9	Stem cell strategies for the cure of T1D.	90
10	Demographic data for patient groups GI, GII, GIII, T1DM	116
11	Body Mass Index for patient groups GI, GII, GIII, T1DM	117
12	Blood Pressure for patient groups GI, GII, GIII, T1DM	118
13	Fasting Plasma Glucose Level (mg/dl) in patient groups Group I, Group II, and Group III control group.	121

 List of Figures

Number	Title	Page
14	Glycosylated hemoglobin levels HbA1C (%) in patient groups Group I, Group II, and Group III control group.	121
15	Insulin Dose in patient groups Group I, Group II, and Group III control group.	121
16	AST and ALT Group I, Group II, and Group III Control group	122
17	Lipid Profile Group I, Group II and Group III Control group	124
18	Kidney Function Test Group I, Group II and Group III Control group	126
19	Estimated Glomerular Filtration Rate Group I, Group II and Group III Control group	126
20	Estimated ACR Group I, Group II and Group III Control group	128
21	Estimated uNGAL Group I, Group II and Group III Control group	128
22	NGAL in relation to family history of diabetes mellitus in patients with type 1 diabetes mellitus Group I and Group II	130
23	Albumin/creatinine ratio in relation to family history of diabetes mellitus in patients with type 1 diabetes mellitus Group I and Group II	130
24	NGAL in relation to family history of Cardiovascular Disease in type 1 diabetics Group I and Group II	132
25	Albumin/creatinine ratio in relation to family history of Cardiovascular Disease in type 1 diabetics Group I and Group II	132
26	NGAL in relation to family history of Renal Disease in type 1 diabetics Group I and Group II	134

 List of Figures

Number	Title	Page
27	Albumin/creatinine ratio in relation to family history of Renal Disease in type 1 diabetics Group I and Group II	134
28	Correlation of Diabetes marker and NGAL in Group I	135
29	Correlation of Liver function test and NGAL in Group I	136
30	Correlation of Lipid profile test and NGAL in Group I	136
31	Correlation of Kidney Function test and NGAL in Group I	137
32	Correlation of Blood Pressure and NGAL in Group I	138
33	Correlation of Diabetes marker and NGAL in Group II	139
34	Correlation of Liver function test and NGAL Group II	139
35	Correlation of Lipid profile test and NGAL of Group II	140
36	Correlation of Kidney Function test and NGAL of Group II	141